Lytic

General Information


DRACP ID  DRACP00338

Peptide Name   Lytic

Sequence  KLlLKlLkkLLKlLKKK

Sequence Length  17

UniProt ID  Not available

PubChem CID  Not available

Origin  Interleukin-4 receptor a (IL-4Ra) chain

Type  Synthetic peptide

Classification

  

Active ACP Cancer targeted peptides



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
BxPC-3 Pancreatic ductal adenocarcinoma Carcinoma IC50=37.1 μmol/L WST-1 assay 24 h 1
SU.86.86 Pancreatic adenocarcinoma Carcinoma IC50=28.0 μmol/L WST-1 assay 24 h 1
KB Human papillomavirus-related endocervical adenocarcinoma Carcinoma IC50=37.4 μmol/L WST-1 assay 24 h 1
T98G Glioblastoma Blastoma IC50=77.3 μmol/L WST-1 assay 24 h 1
A172 Glioblastoma Blastoma IC50=30.5 μmol/L WST-1 assay 24 h 1
NCI-H322 Minimally invasive lung adenocarcinoma Carcinoma IC50=27.1 μmol/L WST-1 assay 24 h 1
MDA-MB-231 Breast adenocarcinoma Carcinoma IC50=18.5 μmol/L WST-1 assay 24 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Targeting Interleukin-4 Receptor α

Affinity  Not available

Mechanism  The IL-4Rα–lytic peptide contains a target moiety to bind to IL-4Rα and a cellular toxic lytic peptide that selectively kills cancer cells

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  l=D-Leucine; k=D-Lysine

Chiral  Mix



Physicochemical Information


Formula  C72H130N18O8

Absent amino acids  ACDEFGHIMNPQRSTVWY

Common amino acids  KL

Mass  166152

Pl  11.5

Basic residues  6

Acidic residues  0

Hydrophobic residues  6

Net charge  6

Boman Index  -378

Hydrophobicity  -3.53

Aliphatic Index  137.65

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 22084165

Title  Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy

Doi 10.1158/1535-7163.MCT-11-0363

Year  2012

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.